^
    Back
    Association details:
    Biomarker:ALK F1174L
    Cancer:Non Small Cell Lung Cancer
    Drug:Zykadia (ceritinib) (ALK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Fusion detection and longitudinal circulating tumor DNA (ctDNA) profiling in ALK+ non-small cell lung cancer (NSCLC) patients.

    Published date:
    05/16/2018
    Excerpt:
    LB was performed at diagnosis (n = 10), at each radiologic evaluation (n = 75) and at the time of progressive disease (PD) (n = 34) in 35 FISH/RNAseq confirmed ALK+ NSCLC patients, treated with ALK-TKI....ALK resistance mutations were detected in samples collected at PD under crizotinib (L1196M+C1156Y), ceritinib (F1174L), brigatinib (F1174V, F1174L+G1202R, D1203N, R1192P) and lorlatinib (F1174L+G1202R).
    DOI:
    10.1200/JCO.2018.36.15_suppl.e21031
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Sci
    Title:

    Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer

    Excerpt:
    G1202R, F1174C/L/V, and G1123S mutations have been found to be ceritinib‐resistant in an analysis of patients treated with ceritinib after crizotinib
    DOI:
    10.1111/cas.13504